At the WIN Symposium, a researcher from Sheba Medical Center discussed ongoing efforts to develop a 22-gene signature for predicting brain metastasis in NSCLC.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
Molecular features in primary and recurrent glioblastomas indicated that key initiator mutations turned up years before diagnosis, often persisting in recurrent tumors.
Using RNA sequence data from the Cancer Genome Atlas and the Chinese Glioma Genome Atlas, researchers identified six genes with expression ties to overall survival.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
This embargo-free strategy represents "an entirely new way of doing research" into rare pediatric cancers, where time is of the essence.
A new analysis of transcriptome and tumor growth data uncovered distinct expression-based tumor clusters and treatment responses in males and females.
Researchers identified germline and somatic changes that marked low-grade and high-grade cases in adults and children with a condition called neurofibromatosis 1.
In Science this week: genome-wide chromatin accessibility profiles of The Cancer Genome Atlas tumors, and more.
Holden Thorp is to be the new editor-in-chief of Science and its related journals.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.
In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.